{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016260","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.165673+00:00","generated_at":"2026-06-02T01:52:48.242035+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cassava Sciences stockholders elect three directors, ratify auditor, approve say-on-pay at 2024 annual meeting","bullets":["Quorum of ~62% (26,979,468 shares) represented at May 9, 2024 annual meeting.","Three director nominees elected: Barbier (10.8M for), Robertson (8.9M for), Scannon (10.9M for).","Ratification of Ernst & Young as auditor approved (26.5M for, 0.4M against).","Advisory vote on 2023 executive compensation approved (9.4M for, 1.3M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016260","json":"https://secwatch.observer/filing/0001437749-24-016260.json","markdown":"https://secwatch.observer/filing/0001437749-24-016260.md","text":"https://secwatch.observer/filing/0001437749-24-016260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/sava20240513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:52:48.242035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"083407cb04dfcb8c9d3d11fa2ef83422bc70a51e","claim":"FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on 2023 executive compensation at the 2024-05-09 meeting.","evidence_excerpt":"The 2023 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 9,403,571 1,338,907 526,173 15,710,817","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"0caa451988116ec3f34dc470bccba2c00518c6eb","claim":"FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2024-05-09 meeting.","evidence_excerpt":"Three (3) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Remi Barbier 10,768,599 500,052 15,710,817 Sanford R. Robertson 8,944,665 2,323,986 15,710,817 Patrick J. Scannon, M.D., Ph.D. 10,891,367 377,284 15,710,817","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"bef07bf09860047ff221fc23ff48eb1704334f89","claim":"FILANA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-09 meeting.","evidence_excerpt":"The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following votes: For Against Abstain 26,461,553 380,036 137,879","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}